Theo Manschreck to Antipsychotic Agents
This is a "connection" page, showing publications Theo Manschreck has written about Antipsychotic Agents.
Connection Strength
2.433
-
Boshes RA, Manschreck TC. Less is more Redux: Scheduled intermittent dosing to protect/prevent cognitive deterioration in schizophrenia. Med Hypotheses. 2016 May; 90:79-81.
Score: 0.508
-
Osser DN, Roudsari MJ, Manschreck T. The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia. Harv Rev Psychiatry. 2013 Jan-Feb; 21(1):18-40.
Score: 0.406
-
Manschreck TC, Boshes RA. The CATIE schizophrenia trial: results, impact, controversy. Harv Rev Psychiatry. 2007 Sep-Oct; 15(5):245-58.
Score: 0.281
-
Manschreck TC, Khan NL. Recent advances in the treatment of delusional disorder. Can J Psychiatry. 2006 Feb; 51(2):114-9.
Score: 0.251
-
Boshes RA, Manschreck TC. Review of antipsychotic medication administration: a proposal of intermittent dosing. Schizophr Bull. 2002; 28(2):203-22.
Score: 0.189
-
Manschreck TC, Redmond DA, Candela SF, Maher BA. Effects of clozapine on psychiatric symptoms, cognition, and functional outcome in schizophrenia. J Neuropsychiatry Clin Neurosci. 1999; 11(4):481-9.
Score: 0.154
-
Buckley PF, Schooler NR, Goff DC, Kopelowicz A, Lauriello J, Manschreck TC, Mendelowitz A, Miller DD, Wilson DR, Ames D, Bustillo JR, Kane JM, Looney SW. Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study. Psychiatr Serv. 2016 12 01; 67(12):1370-1372.
Score: 0.130
-
Buckley PF, Schooler NR, Goff DC, Hsiao J, Kopelowicz A, Lauriello J, Manschreck T, Mendelowitz AJ, Miller del D, Severe JB, Wilson DR, Ames D, Bustillo J, Mintz J, Kane JM. Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. Schizophr Bull. 2015 Mar; 41(2):449-59.
Score: 0.112
-
Goff DC, McEvoy JP, Citrome L, Mech AW, Bustillo JR, Gil R, Buckley P, Manschreck TC, Achtyes ED, Macklin EA. High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study. J Clin Psychopharmacol. 2013 Aug; 33(4):485-90.
Score: 0.106
-
Stroup TS, Appelbaum PS, Gu H, Hays S, Swartz MS, Keefe RS, Kim SY, Manschreck TC, Boshes RA, McEvoy JP, Lieberman JA. Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study. Schizophr Res. 2011 Aug; 130(1-3):47-52.
Score: 0.091
-
Boshes RA, Manschreck TC, Desrosiers J, Candela S, Hanrahan-Boshes M. Initiation of clozapine therapy in a patient with preexisting leukopenia: a discussion of the rationale of current treatment options. Ann Clin Psychiatry. 2001 Dec; 13(4):233-7.
Score: 0.047
-
Pillai A, Schooler NR, Peter D, Looney SW, Goff DC, Kopelowicz A, Lauriello J, Manschreck T, Mendelowitz A, Miller DD, Severe JB, Wilson DR, Ames D, Bustillo J, Kane JM, Buckley PF. Predicting relapse in schizophrenia: Is BDNF a plausible biological marker? Schizophr Res. 2018 03; 193:263-268.
Score: 0.035
-
Manschreck TC. Delusional disorder: the recognition and management of paranoia. J Clin Psychiatry. 1996; 57 Suppl 3:32-8; discussion 49.
Score: 0.031
-
Manschreck TC, Maher BA, Rosenthal JE, Berner J. Reduced primacy and related features in schizophrenia. Schizophr Res. 1991 Jul-Aug; 5(1):35-41.
Score: 0.023
-
Goff DC, Lamberti JS, Leon AC, Green MF, Miller AL, Patel J, Manschreck T, Freudenreich O, Johnson SA. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology. 2008 Feb; 33(3):465-72.
Score: 0.017
-
Stroup S, Appelbaum P, Swartz M, Patel M, Davis S, Jeste D, Kim S, Keefe R, Manschreck T, McEvoy J, Lieberman J. Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophr Res. 2005 Dec 01; 80(1):1-8.
Score: 0.015
-
Manschreck TC, Ames D. Neurologic features and psychopathology in schizophrenic disorders. Biol Psychiatry. 1984 May; 19(5):703-19.
Score: 0.014
-
Manschreck TC, Maher BA, Rucklos ME, Vereen DR. Disturbed voluntary motor activity in schizophrenic disorder. Psychol Med. 1982 Feb; 12(1):73-84.
Score: 0.012
-
Manschreck TC, Maher BA, Ader DN. Formal thought disorder, the type-token ratio and disturbed voluntary motor movement in schizophrenia. Br J Psychiatry. 1981 Jul; 139:7-15.
Score: 0.011